Can antigenicity counterbalance tumor low absorbed dose in targeted alpha therapy?
Preclinical and clinical studies increasingly show that the immune response plays a major role in radiotherapy.
Here, we investigated the role of major histocompatibility complex class I (MHC-I) molecules recognized by cytotoxic CD8+ T cells in the response to targeted alpha therapy (TAT).
POUGET Jean-Pierre;
PARACH A;
DAVID T;
KARAM Jihad;
BRUCHERTSEIFER Frank;
MORGENSTERN Alfred;
JARLIER Marta;
BARDIES M;
DESHAYES Emmanuel;
GUDIN-DE-VALLERIN A;
BOISSIERE F;
CRAPEZ E;
CONSTANZO Julie;
2025-11-07
Elsevier
JRC143753
1619-7089 (online),
https://www.sciencedirect.com/science/article/pii/S3051291325000047,
https://publications.jrc.ec.europa.eu/repository/handle/JRC143753,
Additional supporting files
| File name | Description | File type | |
|---|
